← Leaderboards
Sharyn D Baker
Ohio State University
$10,060,478
Attributed
$13,361,121
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,361,121 · 9
By mechanism
R01$6,744,711 · 3
P30$4,137,895 · 4
U24$2,073,476 · 1
S10$405,039 · 1
Top collaborators
- Shuiying Hu3 shared
- Blake Peterson3 shared
- Michelle A Rudek3 shared
- Daniel Addison2 shared
- Alexander Sparreboom2 shared
- Michael A. Carducci1 shared
Most similar at Ohio State University
Same institution · by research overlap
- William G Blum$1,308,600
- Blake Peterson$11,402,719
- Shuiying Hu$2,114,418
- Daniel Addison$3,345,439
- Donna F Kusewitt$2,059,082
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsSamplingPharmacodynamicsFundingFutureAntineoplastic AgentsServicesLaboratoriesDosePre-ClinicalLeadValidationResource SharingChildEnsureReportingResearch DesignClinical TrialsEvaluationQuality ControlCell LineMediatingCancer CenterIn Vivo
Grant awards (39)
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$746,337
R01 · FY2025 · HL
Targeting neuronal transport to ameliorate vincristine neurotoxicity$652,168
R01 · FY2025 · CA
Shared Resource Management$276,197
P30 · FY2025 · CA · contact PI
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$730,587
R01 · FY2024 · HL
Targeting neuronal transport to ameliorate vincristine neurotoxicity$620,870
R01 · FY2024 · CA
Shared Resource Management$280,943
P30 · FY2024 · CA · contact PI
Targeting neuronal transport to ameliorate vincristine neurotoxicity$645,896
R01 · FY2023 · CA
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$505,279
U24 · FY2023 · CA
Shared Resource Management$280,939
P30 · FY2023 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$509,249
U24 · FY2022 · CA
Shared Resource Management$280,939
P30 · FY2022 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$521,484
U24 · FY2021 · CA
Shared Resource Management$280,939
P30 · FY2021 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$537,464
U24 · FY2020 · CA
Tyrosine kinase inhibitors for the treatment of childhood AML$333,086
R01 · FY2019 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$343,388
R01 · FY2018 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$343,388
R01 · FY2017 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$343,388
R01 · FY2016 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$314,867
R01 · FY2015 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$327,998
R01 · FY2014 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$317,854
R01 · FY2013 · CA · contact PI
Pharmacokinetics Program$802
P30 · FY2013 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$338,142
R01 · FY2012 · CA · contact PI
Pharmacokinetics Program$237,486
P30 · FY2012 · CA · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$338,142
R01 · FY2011 · CA · contact PI
Pharmacokinetics Program$267,247
P30 · FY2011 · CA · contact PI
AB SCIEX QTRAP 5500 System$405,039
S10 · FY2010 · RR · contact PI
Tyrosine kinase inhibitors for the treatment of childhood AML$348,600
R01 · FY2010 · CA · contact PI
Pharmacokinetics Program$286,354
P30 · FY2010 · CA · contact PI
Pharmacokinetics Program$279,593
P30 · FY2009 · CA · contact PI
PHARMACOLOGY ANALYTIC$93,482
P30 · FY2009 · CA · contact PI
Pharmacokinetics Program$153,593
P30 · FY2008 · CA · contact PI
PHARMACOLOGY ANALYTIC$114,285
P30 · FY2007 · CA · contact PI
PHARMACOLOGY ANALYTIC$114,285
P30 · FY2006 · CA · contact PI
Core--Pharmacology Analytic Facility$250,404
P30 · FY2002 · CA
Core--Pharmacology Analytic Facility$250,404
P30 · FY2002 · CA
Core--Pharmacology Analytic Facility$250,404
P30 · FY2001 · CA
Core--Pharmacology Analytic Facility$250,404
P30 · FY2001 · CA
Core--Pharmacology Analytic Facility$189,195
P30 · FY2001 · CA